Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing is planned for late 2004/early 2005 based on positive Phase III results. I.V. infusion formulation of ibandronate would be the first injectable bisphosphonate for osteoporosis, administered once every two or three months.
You may also be interested in...
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.
Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint
A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain